On November 30, the fourth batch of centralized procurement of high-value medical consumables organized by the state was opened in Tianjin, resulting in the proposed selection results.
[Today's headlines]
The fourth batch of countries organized the collection of high-value medical consumables to produce proposed selection results, with an average price reduction of about 70%
On November 30, the fourth batch of centralized procurement of high-value medical consumables organized by the state was opened in Tianjin, resulting in the proposed selection results. This collection covered intraocular lenses and high-value medical consumables related to sports medicine. Based on pre-collection prices, the market size of the products collected this time was about 15.5 billion yuan, including 6.5 billion yuan for 11 types of intraocular consumables and 9 billion yuan for 19 types of sports medicine consumables. The average price reduction for products selected in this collection is about 70%. Among them, the average price reduction for artificial crystal consumables is 60%. It is estimated that the annual cost savings will be 3.9 billion yuan, and the average price reduction of sports medicine consumables will be 74%. It is estimated that the annual cost savings will be 6.7 billion yuan. This collection has widely benefited cataract patients who have received crystal implants, as well as patients who need sports medicine surgery due to labor or sports muscle ligament damage. The public has a strong sense of satisfaction.
[General outlook]
US stocks rose strongly in November, and the Dow recorded its biggest monthly gain since October 2022
At the close overnight, the Dow rose 520.47 points, or 1.47%, to 35950.89 points; the NASDAQ fell 32.27 points, or 0.23%, to 14226.22 points; and the S&P 500 index rose 17.22 points, or 0.38%, to 4567.80 points. Tesla (TSLA.US) fell 1.66%, and Nvidia (NVDA.US) fell 2.85%. The Nasdaq China Golden Dragon Index closed up 0.08%, Alibaba (BABA.US) rose 0.28%, and Pinduoduo (PDD.US) rose more than 4%, surpassing Alibaba's closing market value. Thursday is the last trading day in November.
U.S. stocks rose strongly in November, and the Dow rose 8.77%, recording the biggest monthly increase since October 2022. The NASDAQ rose 10.7% and the S&P 500 index rose 8.92%. Both recorded their best monthly performance since July 2022. Furthermore, the S&P 500 index also recorded its biggest November increase since 1928.
The Hong Kong stock ADR index rose. In proportional terms, it closed at 1,7046 points, up 4.45 points or 0.03% from the Hong Kong closing market.
[Hot preview]
Hong Kong Stock Exchange: Proposes that the securities market and derivatives market can continue to provide trading, settlement and settlement services in bad weather
The Zhitong Finance App learned that the Hong Kong Stock Exchange published a consultation paper today to put forward suggestions on maintaining the normal operation of the Hong Kong securities and derivatives market in bad weather, and to seek market opinions on the operating model and related arrangements. The consultation period is two months until January 26, 2024.
“Shenzhen's Certain Measures to Accelerate Technological Transformation and Upgrading of Industrial Enterprises under the New Situation” was issued
The General Office of the Shenzhen Municipal People's Government issued “Certain Measures of Shenzhen to Accelerate Technological Transformation and Upgrading of Industrial Enterprises under the New Situation”. Among them, it is mentioned that a number of major technological transformation projects will be promoted. Stronger efforts are being made to attract industrial enterprises with additional investment intentions to launch a number of high-quality production capacity and key projects in Shenzhen to promote enterprises to increase capital and expand production and improve quality development. Major technological transformation projects with a total investment of 500 million yuan or more implemented by industrial enterprises in Shenzhen are funded according to no more than 10% of the total investment and construction costs approved by industrial enterprises. The maximum funding limit for a single project is 100 million yuan.
People familiar with the matter: Blizzard has already negotiated with NetEase, Tencent, etc., and the time for the return of the national service is still undecided
On November 30, Tencent's “Rubik's Cube Studio” is suspected to be broadcasting World of Warcraft on Station B. As of press release, the live broadcast has been discontinued, but the “World of Warcraft” related logo can still be seen. Recently, a reporter from Surge News exclusively learned from people familiar with the matter that Blizzard is already in talks with a number of game manufacturers, including NetEase and Tencent, about the return of the national service, but so far there are no confirmed partners or a specific return time, and Tencent has yet to respond to this matter. According to public information, Rubik's Cube Studio is one of the four major studio groups in Tencent's interactive entertainment business group.
Xianruida Medical-B (06669): ACOART LITOS's IDE application was approved by the US FDA
According to the Zhitong Finance App, Xianruida Medical-B (06669) announced that the company's product, Paclitaxel-coated percutaneous angioplasty (PTA) balloon catheter ACart Litos, received approval from the US Food and Drug Administration on November 29, 2023 for its Investigational Device Exemption (IDE) application.
Ideal Car-W (02015) will start overseas next year and enter the first batch of countries in the Middle East
The reporter learned from a number of people familiar with the matter that Ideal Auto plans to go overseas in 2024. The first batch of markets it will enter will be Middle Eastern countries such as the United Arab Emirates and Saudi Arabia, and may also include some North African countries. The first batch of overseas models was the Ideal L9. Depending on the acceptance level of overseas consumers, the Ideal L8 and Ideal L7 may also be added.
The news that the Huawei nova 12 phone has passed 3C certification is tentatively scheduled to be released next month
Recently, a new Huawei model with the FIN-AL60 passed the national 3C certification. It is expected to be a Huawei nova 12 phone. According to certification information, this new model is manufactured by BYD Electronics (00285) Co., Ltd. in Changsha and supports a maximum of 66W charging power. The product type is a TD-LTE digital mobile phone, and is not expected to support 5G communication.
Kuaishou: Commercial promotion and marketing of third party miniseries will be cut off in the near future
The reporter learned from people familiar with the matter that Kuaishou plans to cut off the commercial promotion and distribution of third-party miniseries in the near future, and focus on developing the native micro-drama ecosystem and commercial links based on Kuaishou applets and Kuaishou's internal links. This move will help strengthen the review and operation of the platform's own mini-dramas.
MODERN DENTAL (03600)'s total revenue of HK$2,363 billion in the first three quarters increased by about 12.7% year-on-year
According to the Zhitong Finance App, MODERN DENTAL (03600) announced that although summer (usually a low season for the dental industry) was within the third quarter, the Group continued to face steady and rising demand for its products from the Group's existing, old and new customers. The rise in demand is mainly driven by the global trend of digitalization. This move continues to accelerate the integration of the denture industry, prompting the Group to further increase its market share in the industry. The Group's continuous transformation of digitalization is expected to improve the customer and patient experience, enabling the Group to stand out from its competitors and outperform its peers. The trend of integration in the denture industry clearly continues, and with the addition of production facilities in Vietnam, the Group has the right to further enhance its market position and protect profits.
Alibaba Pictures (01060) completes acquisition of 100% equity interest in live performance provider Pony Media from Alibaba Holdings (09988)
According to the Zhitong Finance App, Alibaba Pictures (01060) announced that all the prerequisites for the $167 million acquisition of 100% of the shares of live performance supplier Pony Media (target company) from Alibaba Holdings (09988) have been met, and the transaction has been carried out on November 30, 2023 in accordance with the terms and conditions of the share purchase agreement. In accordance with the terms and conditions of the share purchase agreement, the company has distributed and issued a total of 2,513 billion worth of shares to the seller Alibaba Investment at an issue price of HK$0.52 per share. As a result, the target company has become a wholly-owned subsidiary of the company.
China Kepei (01890) released annual results: core net profit of 790 million yuan increased 5.3% year-on-year
According to the Zhitong Finance App, China Kepei (01890) released its annual results for the year ended August 31, 2023, with revenue of 1,517 billion yuan (RMB, same below), up 5.4% year on year; profit for the year was 743 million yuan, up 5.5% year on year; core net profit of 790 million yuan, up 5.3% year on year; and profit per share of 0.3701 yuan. The increase in earnings is mainly due to a steady increase in the number of students enrolled in Chinese schools and the average tuition fees.
[Individual stocks are a bit clear]
Heyu-B (02256): Various early research varieties recently revealed excellent clinical data ABSK021 long-term follow-up data further improved
Long-term follow-up data for ABSK021 TGCT indications have been further improved, and the international multi-center phase III clinical trial has progressed smoothly.
ABSK021 shows BIC potential. Compared with the early 6-month data reported in CTOS in 2022, the efficacy data of Pimicotinib's one-year follow-up continued to improve. The ORR assessed by IRC based on Recist1.1 reached 87.5% (28/32, including 3 CR cases) and 66.7% (8/12, including 2 CR cases) in the 50 mg QD cohort and the 25 mg QD cohort, respectively. Compared with similar target drugs, it has strong BIC potential. The international multi-center phase III clinical trial for TGCT indications was approved by the US FDA in March 2023, and the first patient administration in the US was completed on August 2. Previously, administration of the first case in China was completed in April. Furthermore, in January 2023, ABSK021 was granted a breakthrough treatment by the FDA; in June, it was granted priority drug status by the European Medicines Agency, becoming the first potential best candidate drug in the CSF-1R category to receive breakthrough therapy or priority drug qualification in China, the US, and Europe.
Preliminary clinical data of Irpagratinib (ABSK011) showed BIC potential. Irpagratinib (ABSK011) has been observed to have excellent efficacy and safety in previously treated FGF19+ HCC patients, where BID was administered twice daily ORR of 40.7% in the dose group. The ORR of drugs competing with the same target is 7-17%. In terms of progress, it is expected that 2L HCC registered clinical trials will be promoted by the end of 2024.
ABSK043 (oral PD-L1) released preliminary ORR data. There is a large market for ABSK043 (oral PD-L1) oral dosage forms to replace them. The global market size of PD- (L) 1 is already close to 40 billion US dollars in 2022, and the domestic PD- (L) 1 market has exceeded 10 billion RMB. About 80% of the PD- (L) 1 market is suitable for oral PD-L1, and there is plenty of room for future replacement. Currently, there are 7 domestic PD-L1 oral small molecule clinical stages, all of which are in phase I clinical trials. Irpagratinib (ABSK011) is the first drug under development to disclose clinical data. Among 16 patients in the BID dosage group, the ORR was approximately 27% (3/11), showing initial antitumor activity.
ABSK131, a new-generation mTAcosteroid PRMT5 inhibitor, is expected to enter the IND stage in 2024. The target is broad spectrum, and there is great potential for commercialization. The new generation of mTACoPRMT5 inhibitors can selectively inhibit PRMT5*MTA rather than broad-spectrum inhibition of PRMT5. The safety and efficacy are expected to improve significantly compared to the first generation of drugs. Focusing on PRMT5*MTA, the company has identified a number of highly active drug candidates. The first drug candidate, ABSK131, is expected to enter the clinical development stage next year. PRMT5*MTA has great potential for commercialization, and many MNCs participate in the layout. Mutations with missing MTAP genes are common in many tumors. The average mutation rate is 10-15%, lung cancer is 15-20%, and the target patient population base is large. Currently, many MNCs, including GSK, Amgen, and AZ, are participating in the layout.